CHSRI Stock Overview
UBS ETF (CH) - MSCI Switzerland IMI Socially Responsible is an exchange traded fund launched by UBS Fund Management (Switzerland) AG.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
UBS ETF (CH) - MSCI Switzerland IMI Socially Responsible Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF16.91 |
52 Week High | CHF17.59 |
52 Week Low | CHF14.76 |
Beta | 0 |
1 Month Change | -1.81% |
3 Month Change | 4.07% |
1 Year Change | 1.97% |
3 Year Change | -5.32% |
5 Year Change | 26.25% |
Change since IPO | 32.15% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
CHSRI | CH Capital Markets | CH Market | |
---|---|---|---|
7D | -2.1% | -4.5% | -2.1% |
1Y | 2.0% | 27.7% | -3.6% |
Return vs Industry: CHSRI underperformed the Swiss Capital Markets industry which returned 30.6% over the past year.
Return vs Market: CHSRI exceeded the Swiss Market which returned -2.2% over the past year.
Price Volatility
CHSRI volatility | |
---|---|
CHSRI Average Weekly Movement | 1.3% |
Capital Markets Industry Average Movement | 3.2% |
Market Average Movement | 3.5% |
10% most volatile stocks in CH Market | 7.4% |
10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: CHSRI has not had significant price volatility in the past 3 months.
Volatility Over Time: CHSRI's weekly volatility (1%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | n/a |
UBS ETF (CH) - MSCI Switzerland IMI Socially Responsible is an exchange traded fund launched by UBS Fund Management (Switzerland) AG. It is managed by UBS Asset Management. The fund invests in the public equity markets of Switzerland.
UBS ETF (CH) - MSCI Switzerland IMI Socially Responsible Fundamentals Summary
CHSRI fundamental statistics | |
---|---|
Market cap | n/a |
Earnings (TTM) | CHF0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CHSRI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CHSRI income statement (TTM) | |
---|---|
Revenue | CHF0 |
Cost of Revenue | CHF0 |
Gross Profit | CHF0 |
Other Expenses | CHF0 |
Earnings | CHF0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did CHSRI perform over the long term?
See historical performance and comparison